Ignite Creation Date:
2024-05-06 @ 3:19 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04592653
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-07
First Post:
2020-08-24
Brief Title:
Less Frequent IV Dosing Tumor Microenvironment TME Study of Nemvaleukin Alfa ALKS 4230 Monotherapy and in Combination With Pembrolizumab ARTISTRY-3
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Study Overview
Official Title:
Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARTISTRY-3
Brief Summary:
The study will be conducted in 2 cohorts A single-center design for the tumor microenvironment TME cohort Cohort 1 and a multicenter design for the less frequent intravenous IV dosing cohort Cohort 2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None